Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEMATOVAC – Immunogenicity of PCV13 + PPV23 versus Prevenar 20 in lymphoma
2024-517288-22-01Phase 4Suspended
- Sponsor
- CHU de Poitiers
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more comparing PCV13 + PPV23 sequential vaccination with Single-dose Prevenar 20 vaccination (2 arms). Primary endpoint: Primary immunogenicity response comparison. Started Oct 2024; status: suspended.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccinePrevnar 20
03
Conditions
lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)pneumococcal disease
Beyond the preview
Go deeper on 2024-517288-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517288-22-01.